TABLE 4.

The neuroprotection of ginsenoside Rb1 in depression.

Models	Dose of Rb1	Effects	Mechanisms	References
LPS-induced depressive mice	10–20 mg/kg daily for 11 consecutive days	Ameliorating LPS-induced Aepressive-like behaviors	Anti-inflammation, improving impaired Glucocorticoid receptor	Liang et al. (2022)
CUMS mice	5–20 mg/kg for 7 days	Decreasing the immobility time in the FST	Balancing neurotransmitters and decreasing the level of Glu	Guo-Li Wang et al. (2018a)
CUMS mice	4–10 mg/kg for 21 days	Decreasing immobility time in the FST and TST	Balancing neurotransmitters	Yamada et al. (2011)
CSDS mice	35–70 mg/kg daily orally for 28 days	Reversing the social avoidance behavior, anhedonia, and behavioral despair	Enhancing the BDNF signaling and upregulating hippocampal neurogenesis	Jiang et al. (2021a)
CRS rats	6.75–13.5 mg/kg	Ameliorating the memory impairments	Antioxidant; anti-apoptosis; improving synaptic plasticity; restoring the BDNF signaling	Jiang et al. (2021b)
CRS mice	10 mg/kg by intraperitoneal injection for 14 days	Relieving the depression-like behaviors	Anti-inflammation; pro-survival; increasing BDNF expression	Guo et al. (2021)
CMS-exposed mice	20 mg/kg for 4 weeks	Alleviating depressive-like behaviors	Inducing a pro-neurogenic phenotype of microglia, anti-inflammation	Zhang et al. (2021)